See more : Sinomine Resource Group Co., Ltd. (002738.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Cabio Biotech (Wuhan) Co., Ltd. (688089.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cabio Biotech (Wuhan) Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Innolog Holdings Corporation (INHC) Income Statement Analysis – Financial Results
- Advanced Blockchain AG (BWQ.DE) Income Statement Analysis – Financial Results
- Newlox Gold Ventures Corp. (LUX.CN) Income Statement Analysis – Financial Results
- Pact Group Holdings Ltd (PCTGY) Income Statement Analysis – Financial Results
- Hyundai Motor Company (HYMTF) Income Statement Analysis – Financial Results
Cabio Biotech (Wuhan) Co., Ltd. (688089.SS)
About Cabio Biotech (Wuhan) Co., Ltd.
Cabio Biotech (Wuhan) Co., Ltd. develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers. Its products are used in infant formula food, health food, dietary supplements, and other fields for special medical purposes, pet nutrition food, economic animal feed, personal care and cosmetics, and other fields. The company was founded in 1999 and is based in Wuhan, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 443.80M | 433.42M | 351.11M | 323.46M | 311.55M | 286.11M | 228.56M | 189.80M | 181.16M | 186.53M | 200.06M |
| Cost of Revenue | 267.54M | 250.77M | 175.28M | 145.49M | 146.52M | 146.09M | 122.40M | 95.35M | 95.49M | 100.47M | 97.15M |
| Gross Profit | 176.27M | 182.66M | 175.83M | 177.97M | 165.03M | 140.02M | 106.16M | 94.46M | 85.67M | 86.06M | 102.91M |
| Gross Profit Ratio | 39.72% | 42.14% | 50.08% | 55.02% | 52.97% | 48.94% | 46.45% | 49.77% | 47.29% | 46.14% | 51.44% |
| Research & Development | 38.60M | 32.30M | 30.95M | 20.38M | 18.72M | 16.38M | 13.63M | 14.27M | 16.17M | 19.42M | 15.37M |
| General & Administrative | 8.59M | 24.55M | 13.49M | 16.86M | 12.00M | 5.67M | 15.69M | 13.76M | 50.43M | 33.28M | 34.65M |
| Selling & Marketing | 18.71M | 24.81M | 17.69M | 14.62M | 17.47M | 15.36M | 13.02M | 12.31M | 10.69M | 8.00M | 8.73M |
| SG&A | 27.30M | 49.35M | 31.18M | 31.48M | 29.47M | 21.04M | 28.71M | 26.07M | 61.11M | 41.28M | 43.38M |
| Other Expenses | 28.77M | 10.87M | 9.71M | 11.23M | 14.86M | 32.85M | 26.22M | 21.40M | 9.28M | -2.42M | 3.65M |
| Operating Expenses | 94.66M | 92.52M | 71.84M | 63.09M | 63.05M | 50.56M | 44.63M | 44.32M | 63.79M | 43.52M | 46.85M |
| Cost & Expenses | 362.20M | 343.29M | 247.12M | 208.58M | 209.57M | 196.64M | 167.03M | 139.67M | 159.28M | 143.99M | 144.00M |
| Interest Income | 2.09M | 5.44M | 6.98M | 3.90M | 986.45K | 475.52K | 0.00 | 116.30K | 0.00 | 0.00 | 373.60K |
| Interest Expense | 765.05K | 366.11K | 351.44K | 54.44K | 10.59K | 77.99K | 77.95K | 2.39M | 2.56M | 838.92K | 0.00 |
| Depreciation & Amortization | 50.07M | 27.58M | 24.04M | 26.01M | 28.98M | 27.84M | 26.98M | 27.27M | 26.21M | 29.88M | 29.49M |
| EBITDA | 152.92M | 113.91M | 178.01M | 135.78M | 169.88M | 117.30M | 104.26M | 82.34M | 48.09M | 74.67M | 81.44M |
| EBITDA Ratio | 34.46% | 37.27% | 50.41% | 58.38% | 55.38% | 44.47% | 48.35% | 53.15% | 28.51% | 37.67% | 44.90% |
| Operating Income | 81.61M | 134.56M | 117.16M | 124.20M | 143.56M | 81.03M | 51.00M | 33.37M | 16.97M | 45.62M | 51.80M |
| Operating Income Ratio | 18.39% | 31.04% | 33.37% | 38.40% | 46.08% | 28.32% | 22.31% | 17.58% | 9.37% | 24.46% | 25.89% |
| Total Other Income/Expenses | 18.40M | -56.42M | 34.90M | 33.53M | 40.97M | 32.77M | 26.22M | 21.40M | 9.28M | -2.42M | 3.65M |
| Income Before Tax | 100.00M | 78.14M | 152.06M | 157.73M | 139.75M | 113.80M | 77.22M | 54.77M | 26.25M | 43.20M | 55.45M |
| Income Before Tax Ratio | 22.53% | 18.03% | 43.31% | 48.76% | 44.86% | 39.78% | 33.79% | 28.86% | 14.49% | 23.16% | 27.72% |
| Income Tax Expense | 13.63M | 16.55M | 20.77M | 22.80M | 20.00M | 15.97M | 11.63M | 8.42M | 6.71M | 5.54M | 8.75M |
| Net Income | 91.37M | 64.37M | 128.58M | 130.59M | 118.17M | 96.99M | 65.78M | 46.96M | 19.55M | 37.66M | 46.70M |
| Net Income Ratio | 20.59% | 14.85% | 36.62% | 40.37% | 37.93% | 33.90% | 28.78% | 24.74% | 10.79% | 20.19% | 23.34% |
| EPS | 0.54 | 0.38 | 0.77 | 0.78 | 0.70 | 0.77 | 0.52 | 0.37 | 0.16 | 0.42 | 0.53 |
| EPS Diluted | 0.54 | 0.38 | 0.77 | 0.78 | 0.70 | 0.77 | 0.52 | 0.37 | 0.16 | 0.83 | 1.03 |
| Weighted Avg Shares Out | 169.21M | 168.00M | 168.00M | 168.00M | 168.00M | 125.72M | 126.15M | 126.44M | 124.38M | 88.84M | 88.84M |
| Weighted Avg Shares Out (Dil) | 169.21M | 168.00M | 168.00M | 168.00M | 168.00M | 125.72M | 126.15M | 126.44M | 45.45M | 45.45M | 45.45M |
Source: https://incomestatements.info
Category: Stock Reports